Combination therapy for HIV: The effect on inpatient activity, morbidity and mortality of a cohort of patients

International Journal of STD and AIDS

Volumn 9, Issue 2, 1998, Pages 80-87

  Brettle, Ray P ^a   Wilson, Alan ^a   Povey, Sarah ^a   Morris, Sheila ^a   Morgan, Rhoda ^a   Leen, Clifford L S ^a   Hutchinson, Sharon ^b   Lewis, Steff ^b   Gore, Sheila ^c  

^a CITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Admissions; Bed days; Combination therapy; Morbidity; Mortality; Pharmacy costs; Zidovudine

Indexed keywords

ANTIRETROVIRUS AGENT; INDINAVIR; LAMIVUDINE; LOVIRIDE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST CONTROL; DRUG COST; HOSPITAL ADMISSION; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY; PRIORITY JOURNAL;

ANTI-HIV AGENTS; COHORT STUDIES; COST SAVINGS; COSTS AND COST ANALYSIS; DIDANOSINE; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; PROSPECTIVE STUDIES; ZALCITABINE; ZIDOVUDINE;

EID: 0031883043     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/0956462981921729     Document Type: Article

References (19)

1. Beck EJ, Kennelly J, McKevitt C, et al. Changing presentation and survival, service utilisation and costs for AIDS patients: insights from a London referral centre. AIDS 1994;8:379-84
2. Beck EJ, Kennelly J, Mckevitt C, et al. Changing use of hospital services and costs at a London AIDS referral centre, 1983-1989. AIDS 1994;8:367-77
3. Scitovsky AA, Cline MW, Abrams DI. Effects of the use of AZT on the medical care costs of persons with AIDS in the first 12 months. J Acquir Immune Defic Syndr 1990;3:904-12
4. Greco D, Declich S, Pezzotti P, Bellomi G, Visco G. Hospital use by HIV patients in Italy: a retrospective longitudinal study. J Acquir Immune Defic Syndr 1991;4(5):471-9
5. Cosler LE, Lambrinos J. Zidovudine's impact on resource use by patients with symptomatic HIV illness: a large sample analysis. Inquiry 1992;29(3):345-55
6. Beck EJ, Kupek EJ, Petrou SP, et al. Survival and the use and costs of hospital services for London AIDS patients treated with AZT. Int J STD AIDS 1996;7:507-12
7. Moore RD, Hidalgo J, Bareta JC, Chaisson RE. Zidovudine therapy and health resource utilization in AIDS. J Acquir Immune Defic Syndr 1994;7(4):349-54
8. Delta Coordinating Committee. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996;348:283-91
9. Hammer S, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996;335:1081-90
10. Eron JJ, Benoit SL, Jemesk J, et al. Treatment with lamivudine, zidovudine or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimetre. N Engl J Med 1995;333:1662-9
11. Report of the National Working Party on Health Service Implications of HIV Infection (Tayler Report). Scottish Home and Health Department, St Andrews House, Carlton Hill, Edinburgh, May 1987
12. Brettle RP, Gore SM, McNeill A. Outpatient medical care of injection drug use related HIV. Int J STD AIDS 1992;3:96-100
13. Brettle RP, Willcocks, L, Hamilton BA, et al. Outpatient medical care in Edinburgh for IDU related HIV. AIDS Care 1994;6:49-58
14. Brettle RP, McNeil AJ, Gore SM, Bird AG, Leen CSL, Richardson A. Analysis of enrolment, progression, survival, mortality and descriptive covariates in the Edinburgh City Hospital cohort. QJM 1995;88:479-91
15. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR 1987;36:3S-15S
16. Brettle RP, Gore SM, Bird AG, McNeil AJ. Clinical and epidemiological implications of CDC/WHO reclassification of AIDS cases. AIDS 1993;7:531-9
17. Concorde Coordinating Committee. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994;343:871-81
18. Communicable Diseases (Scotland) Unit. Working Group. Acquired Immune Deficiency Syndrome and HIV-related disease in Scotland. Report of a working group convened by the Chief Medical Officer. The Scottish Office, Home and Health Department, CDS (U) Glasgow, March 1993
19. Report of a Working Group. The incidence and prevalence of AIDS and other severe HIV disease in England and Wales for 1992-1997: projections using data to the end of June 1992. Commun Dis Rep 1993;3(suppl 1):S1-S17